tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Abnormalities, Multiple D000015 13 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Acne Vulgaris D000152 35 associated lipids
Adenocarcinoma D000230 166 associated lipids
Adrenal Insufficiency D000309 3 associated lipids
Akinetic Mutism D000405 1 associated lipids
Albuminuria D000419 18 associated lipids
Alopecia D000505 14 associated lipids
Alopecia Areata D000506 6 associated lipids
Alzheimer Disease D000544 76 associated lipids
Amenorrhea D000568 4 associated lipids
Amputation, Traumatic D000673 2 associated lipids
Anemia D000740 21 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Anemia, Hemolytic, Autoimmune D000744 5 associated lipids
Anemia, Refractory D000753 3 associated lipids
Anemia, Refractory, with Excess of Blasts D000754 2 associated lipids
Aneurysm, Dissecting D000784 2 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Hara Y et al. Unresponsiveness to rat cardiac allografts induced by intrathymic injection of donor bone marrow cells and short course of immunosuppression. 1994 Transplant. Proc. pmid:7527955
Guy S et al. Immunosuppression conversion for relief of side effects. 1994 Transplant. Proc. pmid:7527956
Knoop C et al. FK 506 rescue therapy for irreversible airway rejection in heart-lung transplant recipients: report on five cases. 1994 Transplant. Proc. pmid:7527957
Candinas D et al. Efficacy of leflunomide in combination with current immunosuppressive agents in rat cardiac allotransplantation. 1994 Transplant. Proc. pmid:7527959
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. presensitization with suboptimal doses of FK 506 or rapamycin. 1994 Transplant. Proc. pmid:7513476
Nomoto S et al. Cardiotoxicity of long-term intravenous administration of FK506 in rabbits: dose relationship and recovery after discontinuance. 1994 Transplant. Proc. pmid:7513477
Kato H et al. Spontaneous proliferation of peripheral blood mononuclear cells as an indicator for insufficient plasma levels of FK 506 in the early phase after liver transplantation. 1994 Transplant. Proc. pmid:7513481
Nishikawa K et al. Experimental studies of vascularized joint allografts in rats. 1994 Transplant. Proc. pmid:7513482
Douglas CM et al. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7528927
Lhoëst G et al. Isolation and identification of a FK-506 C36-C37 dihydrodiol from erythromycin-induced rabbit liver microsomes. 1994 J Pharm Biomed Anal pmid:7516189
Kraus-Friedmann N and Feng L Reduction of ryanodine binding and cytosolic Ca2+ levels in liver by the immunosuppressant FK506. 1994 Biochem. Pharmacol. pmid:7529023
Ohtsuka S et al. Experimental rat pancreas transplant: surgical technique and immunological considerations. 1994 Surg. Today pmid:7516209
Hisatomi K et al. Limited effectiveness of FK506 administration for ongoing rejection in heterotopic rat heart transplantation. 1994 Surg. Today pmid:7516210
Wolter K et al. Interaction between FK 506 and clarithromycin in a renal transplant patient. 1994 Eur. J. Clin. Pharmacol. pmid:7532134
Konishi M et al. Effects of FK506 on surface antigen expression by regenerating thymocytes after sublethal irradiation in the rat. 1994 Thymus pmid:7532330
Ohtsuka S et al. Mechanism of antibody production in guinea pig to rat discordant xenotransplant: establishment of a simple model by intravenous injection of discordant splenocytes. 1994 Transplant. Proc. pmid:7518130
Todo S et al. Intestinal transplantation at the University of Pittsburgh. 1994 Transplant. Proc. pmid:7518136
Reyes J et al. Lymphoproliferative disease after intestinal transplantation under primary FK 506 immunosuppression. 1994 Transplant. Proc. pmid:7518137
Murase N et al. Small bowel transplantation in sensitized recipients: comparison with heart, kidney, and liver grafts. 1994 Transplant. Proc. pmid:7518139
Pruschy MN et al. Mechanistic studies of a signaling pathway activated by the organic dimerizer FK1012. 1994 Chem. Biol. pmid:9383386
Dumont FJ et al. Quantitative and temporal analysis of the cellular interaction of FK-506 and rapamycin in T-lymphocytes. 1994 J. Pharmacol. Exp. Ther. pmid:7507994
Mueller AR et al. Neurotoxicity after orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518974
Platz KP et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. 1994 Transplantation pmid:7518975
Cakaloglu Y et al. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. 1994 Hepatology pmid:7519161
Luan S et al. Light-regulated, tissue-specific immunophilins in a higher plant. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7508125
Blazar BR et al. FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. 1994 J. Immunol. pmid:7519216
Tze WJ et al. Successful islet allotransplantation in diabetic rats immunosuppressed with FK506: a functional and immunological study. 1994 Metab. Clin. Exp. pmid:7510012
Yamauchi T [Multiple abdominal organ transplantation in swine using FK-506]. 1994 Nihon Geka Gakkai Zasshi pmid:7510015
Hara Y et al. Heterotopic rat heart transplantation to the iliac vessels. 1994 Transplant. Proc. pmid:7520632
Nozaki S et al. Effect of brequinar sodium on accelerated cardiac allograft rejection in presensitized recipients. 1994 Transplant. Proc. pmid:7520633
Masaoka T Problems of bone marrow transplantation in Japan. 1994 Transplant. Proc. pmid:7520634
Surdacka E et al. [New immunosuppressive drugs in transplantation]. 1994 Prz. Lek. pmid:7532870
D'Ambrosio R et al. Multicenter comparison of tacrolimus (FK 506) whole blood concentrations as measured by the Abbott IMX analyzer and enzyme immunoassay with methylene chloride extraction. 1994 Ther Drug Monit pmid:7521979
Metcalfe S et al. FK506 and cyclosporin A each inhibit antigen-specific signaling in the T cell line 171 in the absence of a calcium signal. 1994 Cell. Immunol. pmid:7522130
Calne RY Immunosuppression in liver transplantation. 1994 N. Engl. J. Med. pmid:7523947
Schleuning M et al. Inhibition of cyclosporin A/FK506 resistant, lymphokine-induced T-cell activation by phenothiazine derivatives. 1994 Naunyn Schmiedebergs Arch. Pharmacol. pmid:7523957
Perotti BY et al. HPLC assay for FK 506 and two metabolites in isolated rat hepatocytes and rat liver microsomes. 1994 Pharm. Res. pmid:7524055
Cullen BR and Heitman J Human immunodeficiency virus. Chaperoning a pathogen. 1994 Nature pmid:7526224
Connolly JO et al. Renal arteriopathy associated with FK 506 therapy following liver transplantation. 1994 Nephrol. Dial. Transplant. pmid:7526278
Pham SM et al. Cardiac transplantation at the University of Pittsburgh: 1994 update. 1994 Clin Transpl pmid:7547531
Radanyi C et al. The ability of the immunophilin FKBP59-HBI to interact with the 90-kDa heat shock protein is encoded by its tetratricopeptide repeat domain. 1994 Proc. Natl. Acad. Sci. U.S.A. pmid:7526392
Abu-Elmagd K et al. Hepatic transplantation at the University of Pittsburgh: new horizons and paradigms after 30 years of experience. 1994 Clin Transpl pmid:7547533
Ericzon B et al. Glucose metabolism in liver transplant recipients treated with FK 506 or cyclosporin in the European multicentre study. 1994 Transpl. Int. pmid:11271178
Ko S et al. The pharmacokinetic benefits of newly developed liposome-incorporated FK506. 1994 Transplantation pmid:7526494
Shapiro R et al. Renal transplantation at the University of Pittsburgh: the impact of FK506. 1994 Clin Transpl pmid:7547544
Undre N and Möller A Pharmacokinetic interpretation of FK 506 levels in blood and in plasma during a European randomised study in primary liver transplant patients. The FK 506 European Study Group. 1994 Transpl. Int. pmid:11271189
Bendahan J et al. The effect of administration of FK506 on delayed regeneration in flushed partially hepatectomized livers. 1994 Transplantation pmid:7511255
Chavin KD et al. Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance. 1994 Transplantation pmid:7511258
Yano S et al. Cyclosporin A enhances susceptibility of multi-drug resistant human cancer cells to anti-P-glycoprotein antibody-dependent cytotoxicity of monocytes, but not of lymphocytes. 1994 Jpn. J. Cancer Res. pmid:7511575
Iwata H et al. Suppression of allograft responses by combining alloantigen-specific i.v. pre-sensitization with suboptimal doses of rapamycin. 1994 Int. Immunol. pmid:7511931